E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis: A randomized controlled trial

JAMA

Volumn 283, Issue 13, 2000, Pages 1723-1730

  Angus, Derek C ^a   Birmingham, Mary C ^b   Balk, Robert A ^b   Scannon, Patrick J ^b   Collins, David ^b   Kruse, James A ^b   Graham, Donald R ^b   Dedhia, Harakh V ^b   Homann, Scott ^b   Macintyre, Neil ^b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTOXIN ANTIBODY; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; GRAM NEGATIVE SEPSIS; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; MULTICENTER STUDY; MULTIPLE ORGAN FAILURE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; TREATMENT OUTCOME;

EID: 0034607323     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.283.13.1723     Document Type: Article

References (35)

1. Dellinger RP. From the bench to the bedside: the future of sepsis research. Executive Summary of an American College of Chest Physicians, National Institute of Allergy and Infectious Disease, and National Heart, Lung, and Blood Institute Workshop. Chest. 1997;111:744-753.
2. Linde-Zwirble WT, Angus DC, Carcillo J, Lidicker J, Clermont G, Pinsky MR. Age-specific incidence and outcome of sepsis in the US. Crit Care Med. 1999;27:A33.
3. Centers for Disease Control. Increase in national hospital discharge survey rates for septicemia: United States, 1979-1987. JAMA. 1990;263:937-938.
4. Rangel-Frausto MS, Rittet D, Costigan M, Hwang T, Davis CS, Wenzel RP. The natural history of the systemic inflammatory response syndrome (SIRS): a prospective study. JAMA. 1995;273:117-123.
5. Sands KE, Bates DW, Lanken PN, et al, for the Academic Medical Center Consortium Sepsis Project Working Group. Epidemiology of sepsis syndrome in 8 academic medical centers. JAMA. 1997;278:234-240.
6. Morrison DC, Ryan JL. Endotoxins and disease mechanisms. Annu Rev Med. 1987;38:417-432.
7. Brade H, Brade L, Schade U, et al. Structure, endotoxicity, immunogenicity and antigenicity of bacterial lipopolysaccharides (endotoxins, O-antigens). Prog Clin Biol Res. 1988;272:17-45.
8. Glauser MP, Zanetti G, BaumgartnerJD, Cohen J. Septic shock: pathogenesis. Lancet. 1991;338:732-736.
9. Wheeler AP, Bernard GR. Treating patients with severe sepsis. W Engl J Med. 1999;340:207-214.
10. Greenman RL, Schein RM, Martin MA, et al. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. JAMA. 1991;266:1097-1102.
11. Ziegler EJ, Fisher CJ Jr, Sprung CL, et al. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin: a randomized, double-blind, placebo-controlled trial. N Engl J Med. 1991:324:429-436.
12. Wood DM, Parent JB, Gazzano-Santoro H, et al. Reactivity of monoclonal antibody E5 with endotoxin, I: binding to lipid A and rough ipopolysaccha-rides. Circ Shock. 1992;38:55-62.
13. Young LS, Gascon R, Alam S, Bermudez LE. Monoclonal antibodies for treatment of gram-negative infections. Rev Infect Dis. 1989;11:S1564-S1571.
14. Parent JB, Gazzano-Santoro H, Wood DM, et al. Reactivity of monoclonal antibody E5 with endotoxin, II: binding to short- and long-chain smooth lipopolysaccharides. Circ. Shock. 1992;38:63-73.
15. Romulo RL, Palardy JE, Opal SM. Efficacy of anti-endotoxin monoclonal antibody E5 alone or in combination with ciprofloxacin in neutropenic rats with pseudomonas sepsis. J Infect Dis. 1993:167:126-130.
16. Lundblad R, Edstroem P, Giercksky KE. E5 monoclonal anti-endotoxin antibody improves survival and reduces LPS, TNF and endothelin in lethal rat abdominal sepsis. In: Biologic Response Modifiers. Bethesda, Md: National Institutes of Health; 1993.
17. Inada K, Endo S, Yamashita H, Suzuki M, Yoshida H, Yoshoda M. Inhibitory effect of mouse antiendotoxin monoclonal antibody (E5) on hypotension induced by endotoxin and TNF-alpha. J Jpn Assoc Infect Dis. 1993;67:1108-1114.
18. Harkonen S, Scannon P, Mischak RP, et al. Phase I study of a murine monoclonal anti-lipid A antibody in bacteremic and nonbacteremic patients. Antimicrob Agents Chemother. 1988;32:710-716.
19. Greenberg RN, Wilson KM, Kunz AY, Wedel NI, Gorelick KJ. Observations using antiendotoxin antibody (E5) as adjuvant therapy in humans with suspected, serious, gram-negative sepsis. Crit Care Med. 1992;20:730-735.
20. Bone RC, Balk RA, Fein AM, et al. A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. Crit Care Med. 1995:23:994-1006.
21. Bone RC, Balk RA, Cerra FB, et al, for the Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest. 1992;101:1644-1655.
22. Lan KKG, DeMets DL. More flexible sequential and non-sequential designs in long-term clinical trials. Commun Stat Theor Methods. 1984;13:2339-2353.
23. Council for International Organizations of Medical Sciences Working Group I. International Reportingot Adverse Drug Reactions. Geneva, Switzerland: World Health Organization; 1990.
24. Natanson C, Esposito CJ, Banks SM. The sirens' songs of confirmatory sepsis trials: selection bias and sampling error. Crit Care Med. 1998;26:1927-1931.
25. Zeni F, Freeman B, Natanson C. Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment. Crit Care Med. 1997;25:1095-1100.
26. Angus DC. Discourse on method: measuring the value of new therapies in intensive care. In: Vincent JL, ed. Yearbook of Intensive Care and Emergency Medicine. Berlin, Germany: Springer-Verlag; 1998:263-279.
27. Bone RC, Grodzin CJ, Balk RA. Sepsis: a new hypothesis for pathogenesis of the disease process. Chest. 1997;112:235-243.
28. Willatts SM, Radford S, Leitermann M. Effect of the antiendotoxic agent, taurolidine, in the treatment of sepsis syndrome: a placebo-controlled, double-blind trial. Crit Care Med. 1995;23:1033-1039.
29. Gorelick KJ, Wood DM, Parent JB, et al. Binding characteristics of the antiendotoxin antibody XomenJ-E5 to bacterial whole-cell antigens. In: Faist E, Meakins JL, Schildberg FW, eds. 2nd International Congress on the Immune Consequences of Trauma, Shock and Sepsis: Mechanisms and Therapeutic Approaches. Berlin, Germany: Springer-Verlag; 1993:1212-1217.
30. Seelen MA, Athanassiou P, Lynn WA, et al. The anti-lipid A monoclonal antibody E5 binds to rough gram-negative bacteria, fixes C3, and facilitates binding of bacterial immune complexes to both erythrocytes and monocytes. Immunology. 1995;84:653-661.
31. Bouter AS, van Kessel KPM, Cornelissen JJ, et al. Antibiotics enhance binding of lipid A-specific murine monoclonal antibody E5 to gram-negative bacteria. Int J Antimicrob Agents. 1994;4:191-195.
32. Kobayashi H, Oishi S, Koumoto A, Yoshida T, Matsunaga T, Ogawa M. The inhibitory effect of mouse monoclonal IgM antibody E5 against endotoxin on limulus activity of various lipopolysaccharides. Kansemhogaku Zasshi. 1994;68:314-318.
33. Inada K, Endo S, YamashitaH, Suzuki M, Yoshida H, Yoshida M. Inhibitory effect of mouse antiendotoxin monoclonal antibody (E5) on hypotension induced by endotoxin and TNF-alpha. Kansenshogaku Zasshi. 1993;67:1108-1114.
34. Chen TY, Zapol WM, Greene E, Robinson DR, Rubin RH. Protective effects of E5, an antiendotoxin monoclonal antibody, in the ovine pulmonary circulation. J Appl Physiol. 1993;75:233-239.
35. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial i nfarction. N Engl J Med. 1993;329:673-682.